We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Blood Test to Provide Safe, Early Prenatal Genetic Screening

By LabMedica International staff writers
Posted on 08 Apr 2014
A noninvasive blood test has been developed to enable safe early prenatal detection of fetal chromosome abnormalities such as in Down's syndrome as well as the more challenging detection of microdeletions.

Synapse Diagnostics (Hyderabad, India) now offers "Materni T21 PLUS", a highly accurate prenatal genetic blood test for specific chromosome conditions associated with birth defects. More...
Conducted on blood collected from the mother as early as 10 weeks of pregnancy, genetic abnormalities in the fetus, such as Down's Syndrome and multiple other defects, can be detected early using accurate, cutting-edge technology – a state-of-the-art genomic DNA sequencing based test – providing a clear and precise result which can be easily interpreted. Materni T21 PLUS is the only test in the international market that detects not only abnormalities such as in Down's syndrome but also microdeletion type defects. Microdeletion type abnormalities are difficult to detect, such that parents and clinicians usually spend years after birth trying to diagnose them as underlying the child's symptoms. With this advanced test they can be detected early in pregnancy.

Dr. Samit Sekhar, Managing Director for Synapse Diagnostics India, commented, “Down’s syndrome is a naturally occurring chromosomal arrangement that has always been a part of the human condition, being universally present across racial, gender, or socioeconomic lines, and affecting approximately 1 in 800 live births, although there is considerable variation worldwide. Down's syndrome usually causes varying degrees of intellectual and physical disability in the baby and is associated with various other medical issues.”

The current, amniocentesis, test is not only performed late in pregnancy but is also invasive with a risk of miscarriage. Furthermore, in some cases it cannot definitively pick up the microdeletions. Materni T21 provides a noninvasive alternative for early screening that is safe for both mother and unborn child. With this technology doctors and parents can safely obtain accurate information very early, which also helps mitigate anxiety associated with more aggressive procedures or with the uncertainty of other blood tests that may give only probability-based results.

The Materni T21 Plus test is developed and validated by Sequenom Center for Molecular Medicine (Sequenom CMM), a CAP-accredited and CLIA-certified molecular diagnostics laboratory based in San Diego (CA, USA).

Related Links:

Synapse Diagnostics



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.